Stopping GLP-1 medicines: a plan to limit weight regain
Updated: 4 hours ago
The short answer
Stopping a GLP-1 medicine abruptly commonly leads to weight regain, including when lifestyle counseling continues. In a tirzepatide maintenance trial, a lower ongoing dose held more of the weight loss than stopping, although the full dose held more still. Dr. Sean's five-step plan starts with finding the lowest dose that maintains your weight together with your prescriber. The lower-dose result is evidence for continued tirzepatide treatment; tapering to zero and applying the same schedule to semaglutide remain separate clinical decisions.
What we cover
Why hunger returns when the medicine stops, and how the STEP 1 extension separated weight lost during treatment from weight regained afterward. Primary source
SURMOUNT-4: participants who stopped tirzepatide regained 14.0 percent of body weight over a year even with continued diet and exercise counseling. Primary source
SURMOUNT-MAINTAIN: after initial treatment, the 5 mg weekly group remained about 17 percent below starting weight, compared with about 10 percent after stopping and 22 percent on full dose. Primary source
The five steps: find your maintenance floor; reduce with a prescriber; agree on a regain line; build the food and strength routine first; treat zero as the last step.
Why the weekly weigh-in, eight-week dose holds and monitoring window are Dr. Sean's clinical recommendations rather than the trial protocols.
What an oral maintenance trial found, and why evidence for tapering completely off remains preliminary. Primary source
Timestamps
0:00 The group that kept it off
0:49 Why the weight comes back
1:19 What happened when people stopped
3:00 The trial that changes the plan
4:09 The idea the plan is built on
4:52 Step 1: Aim for your floor
6:09 Step 2: Step down, don't stop
6:35 Step 3: Set your line
7:03 Step 4: Build the floor
7:44 Step 5: Zero is the last step
8:16 The plan in one breath
8:43 Watch next: what the scale shows
References
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564. PMID 35441470. https://doi.org/10.1111/dom.14725
Participants regained about two thirds of their semaglutide-associated weight loss after both the medicine and lifestyle program ended. Evidence type: observational extension of a randomized trial.
Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331:38-48. PMID 38078870. https://doi.org/10.1001/jama.2023.24945
Continued tirzepatide produced further weight loss while switching to placebo led to substantial regain despite counseling. Evidence type: randomized withdrawal trial.
Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet. 2026;407:2305-2318. PMID 42119587. https://doi.org/10.1016/S0140-6736(26)00656-2
A 5 mg maintenance dose retained more weight loss than placebo, while full-dose treatment retained more than 5 mg. Evidence type: randomized maintenance trial.
Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32:2679-2687. PMID 42120723. https://doi.org/10.1038/s41591-026-04386-7
Switching to oral orforglipron retained more weight loss than switching to placebo over 52 weeks. Evidence type: randomized maintenance trial.
Seier S, et al. Tapering semaglutide to the most effective dose: real-world evidence from a digital weight management programme (TAILGATE). ECO 2024, abstract 164. Preliminary conference report. https://conscienhealth.org/wp-content/uploads/2024/05/164Semtapering.pdf
Reported tapering experience in a digital program without establishing an equivalent randomized taper-to-zero protocol. Evidence type: early observational conference report.
Funding: STEP 1 was supported by Novo Nordisk; SURMOUNT-4, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN were funded by Eli Lilly. TAILGATE was a preliminary commercial-program report.
One study explained in plain language every week, with sources attached, plus the free metabolic health guide: https://guides.selfprinciple.org/metabolic
This content is for educational purposes only and is not medical advice. Always consult your healthcare provider for individual care. The views expressed are Dr. Sean Hashmi's own and do not represent his employer.
Never start, stop, or change the dose of any prescription medication without consulting your physician.
Comments